FRUCTOSE-1,6-BISPHOSPHATASE 1
HOMO SAPIENS
State in the Current Structure
| Assembly | Oligomeric State | Construct | Mutations and Modifications | Ligands, Ions and Associated Components | Method and Experimental Conditions | Structure Quality |
|---|---|---|---|---|---|---|
| 1 | Protein homooligomer Homooligomer Protein × 4 PDB declaration: tetrameric(4) Consistent with protein copy count | Chain A; UniProt 1–338 Chain B; UniProt 1–338 Chain C; UniProt 1–338 Chain D; UniProt 1–338 | Not recorded | ROK 4-AMINO-N-[(2-SULFANYLETHYL)CARBAMOYL]BENZENESULFONAMIDE × 4 | X-RAY DIFFRACTION X-ray crystallization conditions:RESERVOIR = 0.1M HEPES, PH7.0, 0.1M AMMONIUM ACETATE, 12% PEG 3350 | Resolution 2.20 Å R-free 0.247 |
| 2 | Protein homooligomer Homooligomer Protein × 4 PDB declaration: tetrameric(4) Consistent with protein copy count | Chain E; UniProt 1–338 Chain F; UniProt 1–338 Chain G; UniProt 1–338 Chain H; UniProt 1–338 | Not recorded | ROK 4-AMINO-N-[(2-SULFANYLETHYL)CARBAMOYL]BENZENESULFONAMIDE × 4 | X-RAY DIFFRACTION X-ray crystallization conditions:RESERVOIR = 0.1M HEPES, PH7.0, 0.1M AMMONIUM ACETATE, 12% PEG 3350 | Resolution 2.20 Å R-free 0.247 |
Other States of the Same Protein in the Database
Each row is a biological assembly of the same UniProt protein in another PDB entry. The “Difference from current entry” column identifies evidence-level differences; no tag means the currently parsed fields agree.
| Other PDB | Difference from Current Entry 2VT5 | Assembly / Oligomeric State | Construct | Mutations and Modifications | Ligands, Ions and Non-polymers | Method and Experimental Conditions | Structure Quality |
|---|---|---|---|---|---|---|---|
| 1FTA FRUCTOSE-1,6-BISPHOSPHATASE(D-FRUCTOSE-1,6-BISPHOSPHATE, 1-PHOSPHOHYDROLASE) (E.C.3.1.3.11) COMPLEXED WITH THE ALLOSTERIC INHIBITOR AMP Deposited 1993-09-27 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer;Protein × 4 PDB declaration: tetrameric |
Chain A
1–337(337 aa)
Chain B
1–337(337 aa)
Chain C
1–337(337 aa)
Chain D
1–337(337 aa)
|
Not recorded | AMP ADENOSINE MONOPHOSPHATE × 4 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 2.30 Å |
| 2JJK FRUCTOSE-1,6-BISPHOSPHATASE(D-FRUCTOSE-1,6-BISPHOSPHATE -1- PHOSPHOHYDROLASE) (E.C.3.1.3.11) COMPLEXED WITH A DUAL BINDING AMP SITE INHIBITOR Deposited 2008-04-09 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer;Protein × 4 PDB declaration: tetrameric |
Chain A
1–338(338 aa)
Chain B
1–338(338 aa)
Chain C
1–338(338 aa)
Chain D
1–338(338 aa)
|
Not recorded | R15 N,N'-(heptane-1,7-diyldicarbamoyl)bis(3-chlorobenzenesulfonamide) × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
RESERVOIR = 0.1M HEPES PH7.0, 0.1M AMMONIUM ACETATE, 12% PEG 3350
|
Resolution 2.00 Å R-free 0.266 |
| 2WBB FRUCTOSE-1,6-BISPHOSPHATASE(D-FRUCTOSE-1,6-BISPHOSPHATE-1- PHOSPHOHYDROLASE) (E.C.3.1.3.11) COMPLEXED WITH AN AMP SITE INHIBITOR Deposited 2009-02-26 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer;Protein × 4 PDB declaration: tetrameric |
Chain A
1–338(338 aa)
Chain B
1–338(338 aa)
Chain C
1–338(338 aa)
Chain D
1–338(338 aa)
|
Not recorded | RO3 N-{[(2Z)-5-BROMO-1,3-THIAZOL-2(3H)-YLIDENE]CARBAMOYL}-4-METHYLBENZENESULFONAMIDE × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
0.1M AMMONIUM ACETATE 0.1M HEPES PH7 25% PEG 3350
|
Resolution 2.22 Å R-free 0.248 |
| 2WBB FRUCTOSE-1,6-BISPHOSPHATASE(D-FRUCTOSE-1,6-BISPHOSPHATE-1- PHOSPHOHYDROLASE) (E.C.3.1.3.11) COMPLEXED WITH AN AMP SITE INHIBITOR Deposited 2009-02-26 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer;Protein × 4 PDB declaration: tetrameric |
Chain E
1–338(338 aa)
Chain F
1–338(338 aa)
Chain G
1–338(338 aa)
Chain H
1–338(338 aa)
|
Not recorded | RO3 N-{[(2Z)-5-BROMO-1,3-THIAZOL-2(3H)-YLIDENE]CARBAMOYL}-4-METHYLBENZENESULFONAMIDE × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
0.1M AMMONIUM ACETATE 0.1M HEPES PH7 25% PEG 3350
|
Resolution 2.22 Å R-free 0.248 |
| 2WBD FRUCTOSE-1,6-BISPHOSPHATASE(D-FRUCTOSE-1,6-BISPHOSPHATE-1- PHOSPHOHYDROLASE) (E.C.3.1.3.11) COMPLEXED WITH AN AMP SITE INHIBITOR Deposited 2009-02-26 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer;Protein × 4 PDB declaration: tetrameric |
Chain A
1–338(338 aa)
Chain B
1–338(338 aa)
Chain C
1–338(338 aa)
Chain D
1–338(338 aa)
|
Not recorded | RO5 N-[(5-bromo-1,3-thiazol-2-yl)carbamoyl]-3-ethylbenzenesulfonamide × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
0.1M AMMONIUM ACETATE, 0.1M HEPES PH 7.0, 15% PEG 3350
|
Resolution 2.40 Å R-free 0.277 |
| 2WBD FRUCTOSE-1,6-BISPHOSPHATASE(D-FRUCTOSE-1,6-BISPHOSPHATE-1- PHOSPHOHYDROLASE) (E.C.3.1.3.11) COMPLEXED WITH AN AMP SITE INHIBITOR Deposited 2009-02-26 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer;Protein × 4 PDB declaration: tetrameric |
Chain E
1–338(338 aa)
Chain F
1–338(338 aa)
Chain G
1–338(338 aa)
Chain H
1–338(338 aa)
|
Not recorded | RO5 N-[(5-bromo-1,3-thiazol-2-yl)carbamoyl]-3-ethylbenzenesulfonamide × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
0.1M AMMONIUM ACETATE, 0.1M HEPES PH 7.0, 15% PEG 3350
|
Resolution 2.40 Å R-free 0.277 |
| 2Y5K Orally active aminopyridines as inhibitors of tetrameric fructose 1,6- bisphosphatase Deposited 2011-01-14 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer;Protein × 4 PDB declaration: tetrameric |
Chain A
1–338(338 aa)
Chain B
1–338(338 aa)
Chain C
1–338(338 aa)
Chain D
1–338(338 aa)
|
Not recorded | YCU 1-[5-(2-METHOXYETHYL)-4-METHYL-THIOPHEN-2-YL]SULFONYL-3-[4-METHOXY-6-(METHYLCARBAMOYLAMINO)PYRIDIN-2-YL]UREA × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
RESERVOIR: 0.1M HEPES, PH 7.0, 0.1 M AMMONIUM ACETATE, 12% PEG 3350.
|
Resolution 2.10 Å R-free 0.296 |
| 2Y5L orally active aminopyridines as inhibitors of tetrameric fructose 1,6- bisphosphatase Deposited 2011-01-14 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer;Protein × 4 PDB declaration: tetrameric |
Chain A
1–338(338 aa)
Chain B
1–338(338 aa)
Chain C
1–338(338 aa)
Chain D
1–338(338 aa)
|
Not recorded | RO8 N-{[(2Z)-5-bromo-1,3-thiazol-2(3H)-ylidene]carbamoyl}-3-chlorobenzenesulfonamide × 4 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 2.20 Å R-free 0.254 |
| 2Y5L orally active aminopyridines as inhibitors of tetrameric fructose 1,6- bisphosphatase Deposited 2011-01-14 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer;Protein × 4 PDB declaration: tetrameric |
Chain E
1–338(338 aa)
Chain F
1–338(338 aa)
Chain G
1–338(338 aa)
Chain H
1–338(338 aa)
|
Not recorded | RO8 N-{[(2Z)-5-bromo-1,3-thiazol-2(3H)-ylidene]carbamoyl}-3-chlorobenzenesulfonamide × 4 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 2.20 Å R-free 0.254 |
| 3A29 Crystal structure of human liver FBPase in complex with tricyclic inhibitor Deposited 2009-05-08 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer;Protein × 4 PDB declaration: tetrameric |
Chain A
2–338(337 aa)
Chain B
2–338(337 aa)
Chain C
2–338(337 aa)
Chain D
2–338(337 aa)
|
Not recorded | 2T0 2-amino-4,5-dihydronaphtho[1,2-d][1,3]thiazol-8-yl dihydrogen phosphate × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 8.5;295 K;8-10% PEG 3350, 0.15M NaCl, 0.1M Tris/HCl, pH 8.5, VAPOR DIFFUSION, HANGING DROP, temperature 295K
|
Resolution 2.60 Å R-free 0.247 |
| 3A29 Crystal structure of human liver FBPase in complex with tricyclic inhibitor Deposited 2009-05-08 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer;Protein × 2 PDB declaration: dimeric |
Chain A
2–338(337 aa)
Chain B
2–338(337 aa)
|
Not recorded | 2T0 2-amino-4,5-dihydronaphtho[1,2-d][1,3]thiazol-8-yl dihydrogen phosphate × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 8.5;295 K;8-10% PEG 3350, 0.15M NaCl, 0.1M Tris/HCl, pH 8.5, VAPOR DIFFUSION, HANGING DROP, temperature 295K
|
Resolution 2.60 Å R-free 0.247 |
| 3A29 Crystal structure of human liver FBPase in complex with tricyclic inhibitor Deposited 2009-05-08 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 3 Protein homooligomer Homooligomer;Protein × 2 PDB declaration: dimeric |
Chain A
2–338(337 aa)
Chain C
2–338(337 aa)
|
Not recorded | 2T0 2-amino-4,5-dihydronaphtho[1,2-d][1,3]thiazol-8-yl dihydrogen phosphate × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 8.5;295 K;8-10% PEG 3350, 0.15M NaCl, 0.1M Tris/HCl, pH 8.5, VAPOR DIFFUSION, HANGING DROP, temperature 295K
|
Resolution 2.60 Å R-free 0.247 |
| 3A29 Crystal structure of human liver FBPase in complex with tricyclic inhibitor Deposited 2009-05-08 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 4 Protein homooligomer Homooligomer;Protein × 2 PDB declaration: dimeric |
Chain B
2–338(337 aa)
Chain D
2–338(337 aa)
|
Not recorded | 2T0 2-amino-4,5-dihydronaphtho[1,2-d][1,3]thiazol-8-yl dihydrogen phosphate × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 8.5;295 K;8-10% PEG 3350, 0.15M NaCl, 0.1M Tris/HCl, pH 8.5, VAPOR DIFFUSION, HANGING DROP, temperature 295K
|
Resolution 2.60 Å R-free 0.247 |
| 3A29 Crystal structure of human liver FBPase in complex with tricyclic inhibitor Deposited 2009-05-08 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 5 Protein homooligomer Homooligomer;Protein × 2 PDB declaration: dimeric |
Chain C
2–338(337 aa)
Chain D
2–338(337 aa)
|
Not recorded | 2T0 2-amino-4,5-dihydronaphtho[1,2-d][1,3]thiazol-8-yl dihydrogen phosphate × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 8.5;295 K;8-10% PEG 3350, 0.15M NaCl, 0.1M Tris/HCl, pH 8.5, VAPOR DIFFUSION, HANGING DROP, temperature 295K
|
Resolution 2.60 Å R-free 0.247 |
| 3KBZ Crystal structure of human liver FBPase in complex with tricyclic inhibitor 6 Deposited 2009-10-20 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer;Protein × 4 PDB declaration: tetrameric |
Chain A
2–338(337 aa)
Chain B
2–338(337 aa)
Chain C
2–338(337 aa)
Chain D
2–338(337 aa)
|
Not recorded | 2T4 {[(2-amino-8H-indeno[1,2-d][1,3]thiazol-4-yl)oxy]methyl}phosphonic acid × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 8.5;295 K;8-10% PEG 3350, 0.15M NaCl, 0.1M Tris/HCl, pH 8.5, VAPOR DIFFUSION, HANGING DROP, temperature 295K
|
Resolution 2.45 Å R-free 0.275 |
| 3KC0 Crystal structure of human liver FBPase in complex with tricyclic inhibitor 10b Deposited 2009-10-20 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer;Protein × 4 PDB declaration: tetrameric |
Chain A
2–338(337 aa)
Chain B
2–338(337 aa)
Chain C
2–338(337 aa)
Chain D
2–338(337 aa)
|
Not recorded | 2T5 [(8H-indeno[1,2-d][1,3]thiazol-4-yloxy)methyl]phosphonic acid × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 8.5;295 K;8-10% PEG 3350, 0.15M NaCl, 0.1M Tris/HCl, pH 8.5, VAPOR DIFFUSION, HANGING DROP, temperature 295K
|
Resolution 2.80 Å R-free 0.254 |
| 3KC1 Crystal structure of human liver FBPase in complex with tricyclic inhibitor 19a Deposited 2009-10-20 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer;Protein × 4 PDB declaration: tetrameric |
Chain A
2–338(337 aa)
Chain B
2–338(337 aa)
Chain C
2–338(337 aa)
Chain D
2–338(337 aa)
|
Not recorded | 2T6 {[(7-carbamoyl-8H-indeno[1,2-d][1,3]thiazol-4-yl)oxy]methyl}phosphonic acid × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 8.5;295 K;8-10% PEG 3350, 0.15M NaCl, 0.1M Tris/HCl, pH 8.5, VAPOR DIFFUSION, HANGING DROP, temperature 295K
|
Resolution 2.25 Å R-free 0.262 |
| 4MJO Human liver fructose-1,6-bisphosphatase(d-fructose-1,6-bisphosphate, 1-phosphohydrolase) (e.c.3.1.3.11) complexed with the allosteric inhibitor 3 Deposited 2013-09-04 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer;Protein × 4 PDB declaration: tetrameric |
Chain A
1–338(338 aa)
Chain B
1–338(338 aa)
Chain C
1–338(338 aa)
Chain D
1–338(338 aa)
|
Not recorded | 2C1 N-({4-bromo-6-[(methylcarbamoyl)amino]pyridin-2-yl}carbamoyl)-5-(2-methoxyethyl)-4-methylthiophene-2-sulfonamide × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 7;300 K;0.1 M ammonium acetate and 12% polyethylenglycol 3350 in 0.1 M HEPES, pH 7, VAPOR DIFFUSION, SITTING DROP, temperature 300K
|
Resolution 2.40 Å R-free 0.236 |
| 4MJO Human liver fructose-1,6-bisphosphatase(d-fructose-1,6-bisphosphate, 1-phosphohydrolase) (e.c.3.1.3.11) complexed with the allosteric inhibitor 3 Deposited 2013-09-04 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer;Protein × 4 PDB declaration: tetrameric |
Chain E
1–338(338 aa)
Chain F
1–338(338 aa)
Chain G
1–338(338 aa)
Chain H
1–338(338 aa)
|
Not recorded | 2C1 N-({4-bromo-6-[(methylcarbamoyl)amino]pyridin-2-yl}carbamoyl)-5-(2-methoxyethyl)-4-methylthiophene-2-sulfonamide × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 7;300 K;0.1 M ammonium acetate and 12% polyethylenglycol 3350 in 0.1 M HEPES, pH 7, VAPOR DIFFUSION, SITTING DROP, temperature 300K
|
Resolution 2.40 Å R-free 0.236 |
| 5LDZ Quadruple space group ambiguity due to rotational and translational non-crystallographic symmetry in human liver fructose-1,6-bisphosphatase Deposited 2016-06-29 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer;Protein × 4 PDB declaration: tetrameric |
Chain A
1–338(338 aa)
Chain B
1–338(338 aa)
Chain C
1–338(338 aa)
Chain D
1–338(338 aa)
|
Not recorded | ZN ZINC ION × 6 SO4 SULFATE ION × 20 CL CHLORIDE ION × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 8.5;295 K;0.1 M Tris-HCl pH 8.5, 2 M (NH4)2SO4
|
Resolution 2.20 Å R-free 0.239 |
| 5LDZ Quadruple space group ambiguity due to rotational and translational non-crystallographic symmetry in human liver fructose-1,6-bisphosphatase Deposited 2016-06-29 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer;Protein × 4 PDB declaration: tetrameric |
Chain E
1–338(338 aa)
Chain F
1–338(338 aa)
|
Not recorded | ZN ZINC ION × 6 SO4 SULFATE ION × 18 CL CHLORIDE ION × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 8.5;295 K;0.1 M Tris-HCl pH 8.5, 2 M (NH4)2SO4
|
Resolution 2.20 Å R-free 0.239 |
| 6LW2 The N-arylsulfonyl-indole-2-carboxamide-based inhibitors against fructose-1,6-bisphosphatase Deposited 2020-02-07 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer;Protein × 4 PDB declaration: tetrameric |
Chain A
1–338(338 aa)
Chain B
1–338(338 aa)
Chain C
1–338(338 aa)
Chain D
1–338(338 aa)
|
Not recorded | EW0 7-chloranyl-4-[(3-methoxyphenyl)amino]-N-(4-methoxyphenyl)sulfonyl-1-methyl-indole-2-carboxamide × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;291 K;0.2M Ammonium acetate, 0.1M HEPES, 20% PEG 3350, pH 7.0
|
Resolution 2.40 Å R-free 0.290 |
| 7C9Q Crystal structure of Human liver fructose-1,6-bisphoaphatase complex with Mg2+ and AMP Deposited 2020-06-07 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer;Protein × 4 PDB declaration: tetrameric |
Chain A
1–338(338 aa)
Chain B
1–338(338 aa)
Chain C
1–338(338 aa)
Chain D
1–338(338 aa)
|
Not recorded | AMP ADENOSINE MONOPHOSPHATE × 4 MG MAGNESIUM ION × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;289 K;50mM Hepes pH 7.2, 150mM Sodium chloride, 8% (w/v) PEG 8000
|
Resolution 1.88 Å R-free 0.219 |
| 7CVH Human Fructose-1,6-bisphosphatase 1 in complex with geranylgeranyl diphosphate Deposited 2020-08-26 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer;Protein × 4 PDB declaration: tetrameric |
Chain A
1–338(338 aa)
Chain B
1–338(338 aa)
Chain C
1–338(338 aa)
Chain D
1–338(338 aa)
|
Not recorded | FBP 1,6-di-O-phosphono-beta-D-fructofuranose × 4 MG MAGNESIUM ION × 8 AMP ADENOSINE MONOPHOSPHATE × 4 GRG GERANYLGERANYL DIPHOSPHATE × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 7.5;291 K;28% (v/v) polyethylene glycol 600, 0.1M HEPES
|
Resolution 2.09 Å R-free 0.218 |
| 7CVN The N-arylsulfonyl-indole-2-carboxamide-based inhibitors against fructose-1,6-bisphosphatase Deposited 2020-08-26 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer;Protein × 4 PDB declaration: tetrameric |
Chain A
1–338(338 aa)
Chain B
1–338(338 aa)
Chain C
1–338(338 aa)
Chain D
1–338(338 aa)
|
Not recorded | GJO 4-(3-acetamidophenyl)-N-(4-methoxyphenyl)sulfonyl-7-nitro-1H-indole-2-carboxamide × 4 FBP 1,6-di-O-phosphono-beta-D-fructofuranose × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;291 K;0.2M Ammonium acetate, 0.1M HEPES, 20% PEG 3350, pH 7.0
|
Resolution 2.75 Å R-free 0.234 |
| 7CWE Human Fructose-1,6-bisphosphatase 1 in APO R-state Deposited 2020-08-28 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer;Protein × 4 PDB declaration: tetrameric |
Chain A
1–338(338 aa)
Chain B
1–338(338 aa)
|
Not recorded | MG MAGNESIUM ION × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 7.5;291 K;0.05 M cadmium sulfate, 0.1 M HEPES, pH 7.5, 1 M sodium acetate
|
Resolution 3.00 Å R-free 0.296 |
| 7EZF Indole-2-carboxylic acid derivatives as allosteric inhibitors of fructose-1,6-bisphosphatase Deposited 2021-06-01 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer;Protein × 4 PDB declaration: tetrameric |
Chain A
1–338(338 aa)
Chain B
1–338(338 aa)
Chain C
1–338(338 aa)
Chain D
1–338(338 aa)
|
Not recorded | 0KI 7-chloranyl-5-ethyl-3-(3-hydroxy-3-oxopropyl)-1H-indole-2-carboxylic acid × 4 FBP 1,6-di-O-phosphono-beta-D-fructofuranose × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 7;291 K;0.2M Ammonium acetate, 0.1M HEPES, 20% PEG 3350, pH 7.0
|
Resolution 2.76 Å R-free 0.236 |
| 7EZP Indole-2-carboxylic acid derivatives as allosteric inhibitors of fructose-1,6-bisphosphatase Deposited 2021-06-01 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer;Protein × 4 PDB declaration: tetrameric |
Chain A
1–338(338 aa)
Chain B
1–338(338 aa)
Chain C
1–338(338 aa)
Chain D
1–338(338 aa)
|
Not recorded | FBP 1,6-di-O-phosphono-beta-D-fructofuranose × 4 0GI 3-(3-hydroxy-3-oxopropyl)-5-(2-methylpropyl)-7-nitro-1H-indole-2-carboxylic acid × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 7;291 K;0.2M Ammonium acetate, 0.1M HEPES, 20% PEG 3350, pH 7.0
|
Resolution 2.80 Å R-free 0.256 |
| 7EZR Indole-2-carboxylic acid derivatives as allosteric inhibitors of fructose-1,6-bisphosphatase Deposited 2021-06-01 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer;Protein × 4 PDB declaration: tetrameric |
Chain A
1–338(338 aa)
Chain B
1–338(338 aa)
Chain C
1–338(338 aa)
Chain D
1–338(338 aa)
|
Not recorded | 0H1 5-ethyl-7-nitro-3-[3-oxidanylidene-3-(thiophen-2-ylsulfonylamino)propyl]-1H-indole-2-carboxylic acid × 4 FBP 1,6-di-O-phosphono-beta-D-fructofuranose × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 7;291 K;0.2M Ammonium acetate, 0.1M HEPES, 20% PEG 3350, pH 7.0
|
Resolution 3.27 Å R-free 0.253 |
| 7WVB Human Fructose-1,6-bisphosphatase 1 mutant R50A in APO R-state Deposited 2022-02-10 | Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer;Protein × 4 PDB declaration: tetrameric |
Chain A
1–338(338 aa)
Chain B
1–338(338 aa)
Chain C
1–338(338 aa)
Chain D
1–338(338 aa)
|
Mutation:R50A Mutation:R50A Mutation:R50A Mutation:R50A | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 6.5;293.15 K;0.1M BIS-Tris(pH 6.5), 20% PEGMME 5000, 2.5% sucrose
|
Resolution 2.09 Å R-free 0.233 |
| 9XV1 Crystal Structure of Fructose-1,6-bisphosphatase Complexed with a Covalent Inhibitor Deposited 2025-11-25 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer;Protein × 4 PDB declaration: tetrameric |
Chain A
1–336(336 aa)
Chain B
1–336(336 aa)
Chain C
1–336(336 aa)
Chain D
1–336(336 aa)
|
Not recorded | A1E1G 2-bromanyl-~{N}-[2-[4-[(3-phenylphenyl)carbamoylsulfamoyl]phenyl]ethyl]ethanamide × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;291 K;0.1 M Tris (pH 8.8), 15% (v/v) EtOH
|
Resolution 1.96 Å R-free 0.213 |
22 other PDB entries and 31 assemblies. Open the comparison page and filter oligomeric states
View Construct and Data Evidence
| UniProt name | F16P1_HUMAN |
| Isoform | — |
| PDB entities | 1 |
| Chains and sequence ranges | Author chain A; PDBConstruct 1–338; UniProt 1–338 Author chain B; PDBConstruct 1–338; UniProt 1–338 Author chain C; PDBConstruct 1–338; UniProt 1–338 Author chain D; PDBConstruct 1–338; UniProt 1–338 Author chain E; PDBConstruct 1–338; UniProt 1–338 Author chain F; PDBConstruct 1–338; UniProt 1–338 Author chain G; PDBConstruct 1–338; UniProt 1–338 Author chain H; PDBConstruct 1–338; UniProt 1–338 |